Bio-Rad Wins USDA Contract for Its Pathogen Detection Testing Products
November 13 2018 - 8:30AM
Business Wire
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader
of life science research and clinical diagnostic products, today
announced that the company has been awarded a contract for iQ-Check
real-time PCR pathogen detection test kits and the iQ-Check Prep
Automation System from the United States Department of
Agriculture’s Food Safety and Inspection Service (USDA FSIS).
The contract includes real-time PCR-based tests for pathogens
that include Salmonella spp., Listeria monocytogenes,
Campylobacter, Escherichia coli O157:H7, and Shiga toxin producing
E. coli (STEC) that may be found in raw meat and poultry, ready to
eat meat and poultry, processed egg products, and other food
products and environmental samples. Bio-Rad’s iQ-Check real-time
PCR test kits were selected based on their proven real-time PCR
technology that uses highly specific patented DNA probes to detect
pathogenic bacteria in a sample. USDA FSIS will also incorporate
Bio-Rad’s iQ-Check Prep automation system for high throughput
sample processing and elevated traceability.
“We are pleased to partner with the USDA to help protect the
food supply,” said Annette Tumolo, Bio-Rad President, Life Science
Group. “This is an exciting development for Bio-Rad, reflecting our
strong performance in the area of rapid food pathogen testing
solutions.”
The iQ-Check kits for pathogen detection are routinely used in
food safety programs worldwide, and are recognized by several
renowned international validation organizations. For more
information on Bio-Rad’s complete range of iQ-Check real-time PCR
test kits, please visit www.bio-rad.com/iqcheck.
iQ-Check and Bio-Rad are trademarks of Bio-Rad Laboratories,
Inc. in certain jurisdictions.
About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) is a global
leader in developing, manufacturing, and marketing a broad range of
innovative products for the life science research and clinical
diagnostic markets. With a focus on quality and customer service
for over 65 years, our products advance the discovery process and
improve healthcare. Our customers are university and research
institutions, hospitals, public health and commercial laboratories,
biotechnology, pharmaceutical, as well as applied laboratories that
include food safety and environmental quality. Founded in 1952,
Bio-Rad is based in Hercules, California, and has a global network
of operations with more than 8,000 employees worldwide. Bio-Rad had
revenues exceeding $2.1 billion in 2017. For more information,
please visit www.bio-rad.com.
This release may be deemed to contain certain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These forward-looking statements include,
without limitation, statements we make regarding our expectations
regarding our products. Forward-looking statements generally can be
identified by the use of forward-looking terminology such as
“will”, “believe,” “expect,” “anticipate,” “may,” “plan,” “intend,”
“estimate,” “offers,” or similar expressions or the negative of
those terms or expressions, although not all forward-looking
statements contain these words. Such statements involve risks and
uncertainties, which could cause actual results to vary materially
from those expressed in or indicated by the forward-looking
statements. These risks and uncertainties include our ability to
develop and market new or improved products, our ability to compete
effectively, international legal and regulatory risks, and product
quality and liability issues. For further information regarding our
risks and uncertainties, please refer to the “Risk Factors” and
“Management’s Discussion and Analysis of Financial Condition and
Results of Operation” in Bio-Rad’s public reports filed with the
Securities and Exchange Commission, including our most recent
Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q.
Bio-Rad cautions you not to place undue reliance on forward-looking
statements, which reflect an analysis only and speak only as of the
date hereof. We disclaim any obligation to update these
forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181113005242/en/
Bio-Rad Laboratories, Inc.Tina Cuccia, 510-724-7000Corporate
Communicationstina_cuccia@bio-rad.com
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bio Rad Laboratories (NYSE:BIO)
Historical Stock Chart
From Apr 2023 to Apr 2024